Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
MEHMO syndrome is characterized by severe intellectual deficit, epilepsy, microcephaly, hypogenitalism, and obesity. Growth delay and diabetes are also present. To date, it has been described in seven boys, all of whom died within the first two years of life. The causative gene has been localized to the 21.1-22.13p region of the X chromosome and the syndrome appears to result from mitochondrial dysfunction.
Features include always present findings: Global developmental delay; and very common findings: Microcephaly, Micropenis, Male hypogonadism, and Obesity and others. 59 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 18 | Poor speech, Inability to walk, Seizure |
Head and neck | 5 | Cleft lip, Microcephaly, Cleft palate |
Hormones | 4 | Decreased response to growth hormone stimulation test, Delayed puberty, Male hypogonadism |
Muscles | 3 | Generalized hypotonia, Axial hypotonia, Low muscle tone (hypotonia) |
Eyes | 2 | Strabismus, Nystagmus |
Growth and development | 2 | Decreased response to growth hormone stimulation test, Growth delay |
Arms and legs | 1 | Tapered finger |
EIF2S3 encodes eukaryotic translation initiation factor 2 subunit gamma (472 aa). Member of the eIF2 complex that functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. Highest expression in Cells EBV-transformed lymphocytes (246.4 TPM) and Ovary (197.0 TPM).
MEHMO syndrome is caused by mutations in the EIF2S3 gene on chromosome X.
EIF2S3 is classified as a druggable target with score 0.0.
Genetic testing for EIF2S3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 15 very common features, 14 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
2 publications have been identified in PubMed for MEHMO syndrome. Research spans Review / Meta-Analysis (100%).
Dang Do AN (2025). [PMID: 41207135](https://pubmed.ncbi.nlm.nih.gov/41207135/). *Mol Genet Metab*. [Review / Meta-Analysis]
Gobble MRS (2025). [PMID: 40128490](https://pubmed.ncbi.nlm.nih.gov/40128490/). *Curr Diab Rep*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about MEHMO syndrome